Key Facts
- CAS
- 189691-06-3
- Molecular Weight (MW)
- 1025.2 g/mol
- Half-life
- ~2.7 hours
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- As needed, at least 45 minutes before sexual activity
- Last updated
- 12/14/2025
- Targets
- MC4R (melanocortin-4 receptor)Central nervous system
Overview
—
Protocol
- Dosage Range
- 1.75 mg per dose
- Frequency
- As needed, at least 45 minutes before sexual activity
- Cycle
- Not applicable - on-demand use
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Prefilled autoinjector - no reconstitution needed
Science
Mechanism of Action
Bremelanotide (PT-141) is a synthetic melanocortin receptor agonist that primarily activates MC4R receptors in the central nervous system, leading to increased sexual desire and arousal.
Targets
MC4R (melanocortin-4 receptor)Central nervous system
Studies
- Bremelanotide for hypoactive sexual desire disorder in premenopausal women— Journal/year not available
Benefits
Increased sexual desire in premenopausal women with HSDDImproved sexual satisfactionOn-demand dosing flexibility
Potential Side Effects
- Nausea (most common)
- Flushing
- Headache
- Injection site reactions
- Increased blood pressure
- Dizziness
- Fatigue
References
- FDA Label - VyleesiExternal link · Year —